Regenstrief Institute, Inc., 1050 Wishard Blvd., 6th Floor, Indianapolis, IN 46202, USA.
J Pain Symptom Manage. 2010 Sep;40(3):327-41. doi: 10.1016/j.jpainsymman.2009.12.023. Epub 2010 Jun 26.
Pain and depression are two of the most prevalent and treatable cancer-related symptoms, each present in at least 20%-30% of oncology patients.
To determine the associations of pain and depression with health-related quality of life (HRQL), disability, and health care use in cancer patients.
The Indiana Cancer Pain and Depression study is a randomized clinical trial comparing telecare management vs. usual care for patients with cancer-related pain and/or clinically significant depression. In this article, baseline data on patients enrolled from 16 urban or rural community-based oncology practices are analyzed to test the associations of pain and depression with HRQL, disability, and health care use.
Of the 405 participants, 32% had depression only, 24% pain only, and 44% both depression and pain. The average Hopkins Symptom Checklist 20-item depression score in the 309 depressed participants was 1.64 (on 0-4 scale), and the average Brief Pain Inventory (BPI) severity score in the 274 participants with pain was 5.2 (on 0-10 scale), representing at least moderate levels of symptom severity. Symptom-specific disability was high, with participants reporting an average of 16.8 of the past 28 days (i.e., 60% of their days in the past four weeks) in which they were either confined to bed (5.6 days) or had to reduce their usual activities by 50% (11.2 days) because of pain or depression. Moreover, 176 (43%) participants reported being unable to work because of health-related reasons. Depression and pain had both individual and additive adverse associations with quality of life. Most patients were currently not receiving care from a mental health or pain specialist.
Depression and pain are prevalent and disabling across a wide range of types and phases of cancer, commonly co-occur, and have additive adverse effects. Enhanced detection and management of this disabling symptom dyad is warranted.
疼痛和抑郁是最常见和可治疗的癌症相关症状之一,至少有 20%-30%的肿瘤患者存在这两种症状。
确定疼痛和抑郁与癌症患者的健康相关生活质量(HRQL)、残疾和卫生保健使用之间的关系。
印第安纳癌症疼痛和抑郁研究是一项随机临床试验,比较远程护理管理与常规护理对癌症相关疼痛和/或具有临床意义的抑郁患者的效果。在本文中,分析了从 16 个城市或农村社区肿瘤学实践中招募的患者的基线数据,以检验疼痛和抑郁与 HRQL、残疾和卫生保健使用的关系。
在 405 名参与者中,32%仅有抑郁,24%仅有疼痛,44%同时患有抑郁和疼痛。在 309 名抑郁患者中,平均霍普金斯症状清单 20 项抑郁评分为 1.64(0-4 分),在 274 名有疼痛的患者中,平均简明疼痛量表(BPI)严重程度评分为 5.2(0-10 分),这表明症状严重程度至少为中度。症状特异性残疾程度较高,参与者报告过去 28 天中平均有 16.8 天(即过去四周的 60%)因疼痛或抑郁而卧床(5.6 天)或活动减少 50%(11.2 天)。此外,176 名(43%)参与者报告因健康相关原因无法工作。抑郁和疼痛都对生活质量产生了个体和累加的不良影响。大多数患者目前没有接受心理健康或疼痛专家的治疗。
疼痛和抑郁在广泛的癌症类型和阶段都很普遍,且具有致残性,常同时发生,并具有累加的不良影响。有必要加强对这种致残性症状组合的检测和管理。